{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:21:34Z","timestamp":1780726894819,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007519","name":"Nephcure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007519","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.kint.2024.09.020","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:05:31Z","timestamp":1741921531000},"page":"809-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-2862","authenticated-orcid":false,"given":"Marco","family":"Prunotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin H.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh M.","family":"Tarnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.09.020_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.020_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel v-erbB-related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.kint.2024.09.020_bib4","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1200\/JCO.2009.22.9054","article-title":"Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology","volume":"27","author":"McDermott","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2024.09.020_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib6","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.020_bib7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib8","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib9","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2021.03.028","article-title":"A\u00a0conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy","volume":"100","author":"Lerner","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib11","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4S","key":"10.1016\/j.kint.2024.09.020_bib12","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1003066","article-title":"PLA2R autoantibodies and recurrent membranous nephropathy after transplantation","volume":"363","author":"Stahl","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.020_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1681\/ASN.2012060577","article-title":"Recurrent membranous nephropathy in an allograft caused by IgG3\u03ba targeting the PLA2 receptor","volume":"23","author":"Debiec","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.kint.2023.07.024","article-title":"Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy","volume":"104","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib16","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2024.09.020_bib17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.020_bib19","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","article-title":"An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis","volume":"26","author":"Hoxha","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2024.09.020_bib20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib21","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","article-title":"Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"421C","author":"D\u00e4hnrich","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.kint.2024.09.020_bib24","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ckj\/sfw121","article-title":"Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy","volume":"10","author":"Jullien","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2024.09.020_bib26","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ki.2010.34","article-title":"Membranous nephropathy: recent travels and new roads ahead","volume":"77","author":"Beck","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib27","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib28","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib29","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2024.09.020_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.biochi.2015.08.007","article-title":"Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy","volume":"118","author":"Seitz-Polski","year":"2015","journal-title":"Biochimie"},{"key":"10.1016\/j.kint.2024.09.020_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ekir.2022.12.003","article-title":"Antibody-guided therapy in phospholipase A2 receptor-associated membranous nephropathy","volume":"8","author":"Vink","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.020_bib32","article-title":"Antiphospholipase A(2) receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy","volume":"2014","author":"Behnert","year":"2014","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.kint.2024.09.020_bib33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ekir.2019.11.008","article-title":"Development of a standardized chemiluminescence immunoassay for the detection of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"5","author":"Dahnrich","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2024.09.020_bib34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib35","first-page":"573","article-title":"Diagnostic accuracy of anti-phospholipase A2 receptor (PLA2R) antibodies in idiopathic membranous nephropathy: an Italian experience","volume":"34","author":"Porcelli","year":"2021","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2253922","article-title":"The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China","volume":"45","author":"Guo","year":"2023","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2024.09.020_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281726","article-title":"Can use of the serum anti-PLA2R antibody negate the need for a renal biopsy in primary membranous nephropathy?","volume":"18","author":"Ragy","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2024.09.020_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.09.020_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.09.020_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.09.020_bib42","first-page":"14","article-title":"Community collaborates to address clinical trial endpoints for FSGS","volume":"16","author":"West","year":"2024","journal-title":"Kidney News"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824007762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824007762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:25:45Z","timestamp":1777695945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824007762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0085253824007762"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.020","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc on behalf of International Society of Nephrology and S. Karger AG.","name":"copyright","label":"Copyright"}]}}